What is Leerink Partnrs' Forecast for Illumina Q1 Earnings?

Key Points

• Leerink Partners has lowered their Q1 2026 earnings per share (EPS) estimate for Illumina from $1.09 to $1.05, while the consensus estimate for the current full-year earnings is $4.51 per share.
• Multiple research firms have adjusted their price targets on Illumina, with Evercore ISI reducing it to $132 and Canaccord Genuity raising it to $105, indicating mixed sentiment on the stock.
• Illumina's stock is currently rated as a "Hold" by the consensus, with a target price of $123.56 according to MarketBeat data, following recent changes in analyst ratings.

Illumina, Inc. (NASDAQ:ILMN - Free Report) - Stock analysts at Leerink Partnrs lowered their Q1 2026 earnings per share (EPS) estimates for Illumina in a research note issued to investors on Monday, October 13th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will post earnings of $1.05 per share for the quarter, down from their prior estimate of $1.09. The consensus estimate for Illumina's current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina's Q4 2026 earnings at $1.43 EPS.

A number of other research firms have also recently commented on ILMN. Evercore ISI cut their target price on Illumina from $135.00 to $132.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 7th. Canaccord Genuity Group upped their target price on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Morgan Stanley upped their target price on Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th. Daiwa America cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Finally, Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Six analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $123.56.

Illumina Trading Up 2.2%

Shares of NASDAQ ILMN opened at $93.00 on Thursday. The business's 50 day moving average is $98.10 and its two-hundred day moving average is $90.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina has a 1-year low of $68.70 and a 1-year high of $156.66. The stock has a market capitalization of $14.29 billion, a P/E ratio of 11.77, a PEG ratio of 2.19 and a beta of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period in the previous year, the firm posted $0.36 earnings per share. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS.

Institutional Trading of Illumina

Hedge funds have recently bought and sold shares of the stock. Diversified Trust Co purchased a new stake in Illumina during the first quarter worth $355,000. Bourgeon Capital Management LLC lifted its holdings in Illumina by 76.4% during the second quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company's stock worth $13,538,000 after buying an additional 61,468 shares during the period. GC Wealth Management RIA LLC purchased a new stake in Illumina during the second quarter worth $2,289,000. State of Alaska Department of Revenue lifted its holdings in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock worth $1,469,000 after buying an additional 445 shares during the period. Finally, waypoint wealth counsel purchased a new stake in Illumina during the second quarter worth $321,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.